Aventis Pharma a market performer: Karvy
Karvy Stock Broking has rated Aventis Pharma as a market performer with a target price of Rs 876 in its February 19, 2009 research report. “Revenues for the quarter were up by 32.3% to Rs 2699 million. This was mainly driven by strong growth in domestic formulations business of 18% to Rs 2011 million while exports showed good traction with revenues of Rs 688 million which is much higher than Rs 522 million achieved in the preceeding quarter.
Operating margins were higher at 22% as against 18.6% in the corresponding quarter of the previous year. The margins were better on account of better product mix and traction in exports. Profits for the quarter were up by 68% to Rs 453 million. We downgrade our price target by 20% to Rs 876 based on 14x CY 2009E. We downgrade our rating on the stock to market performer,” says Karvy Stock Broking’s research report.
Tags: calls, daytrading, free calls, intraday, tips
Similar Posts:
Latest Query
- by Sam
Market Stats
Search Our Archives
Research Desk
- Stocks Trading above their 50 day moving average - DMA In Stock Research
- Download free Ebooks based on Technical Analysis In Personal Training
- TOP 100 Stocks with the Highest P/E as on July 14th, 2013 In Stock Research
- TOP 100 Stocks with the Lowest P/E as on July 14th, 2013 In Stock Research
- Charting Pathsala - Your guide to Techincals In Technical Analysis
